Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
77 results about "Beta-peptide" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Β-peptides consist of β amino acids, which have their amino group bonded to the β carbon rather than the α carbon as in the 20 standard biological amino acids. The only common naturally occurring β amino acid is β-alanine; although it is used as a component of larger bioactive molecules, β-peptides in general do not appear in nature. For this reason β-peptide-based antibiotics are being explored as ways of evading antibiotic resistance. Early studies in this field were published in 1996 by the group of Dieter Seebach and that of Samuel Gellman.
Macrocycles useful in the treatment of Alzheimer's disease
Owner:PHARMACIA & UPJOHN CO
Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid- beta peptide (x->/=41)
InactiveUS6114133AImmunoglobulins against animals/humansDisease diagnosisAlzheimer SyndromeDisease cause
This invention provides methods useful in aiding in the diagnosis of Alzheimer's disease. The methods involve measuring the amount of amyloid- beta peptide (x-> / =41) in the cerebrospinal fluid of a patient. High levels of the peptide generally are inconsistent with a diagnosis of Alzheimer's. Low levels of the peptide are consistent with the disease and, with other tests, can provide a positive diagnosis.
Owner:ELAN PHARM INC
Poly-beta-peptides from functionalized beta-lactam monomers and antibacterial compositions containing same
InactiveUS20070087404A1Control over polymerization conditionLarge molecular weightAntibacterial agentsPeptide/protein ingredientsMonomerTetrahydrofuran
Disclosed is a method of making β-polypeptides. The method includes polymerizing β-lactam-containing monomers in the presence of a base initiator and a co-initiator which is not a metal-containing molecule to yield the product β-polypeptides. Specifically disclosed are methods wherein the base initiator is potassium t-butoxide, lithium bis(trimethylsilyl)amide (LiN(TMS)2), potassium bis(trimethyl-silyl)amide, and sodium ethoxide, and the reaction is carried out in a solvent such as chloroform, dichloromethane, dimethylsulfoxide, or tetrahydrofuran.
Owner:WISCONSIN ALUMNI RES FOUND
Use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic a-beta peptides in amyloidopathies
InactiveUS20050113458A1Reduce riskSlow onsetBiocideNervous disorderNR1 NMDA receptorGreek letter beta
The invention relates to the use of NMDA receptor antagonists such as 1-aminocyclohexane derivatives to modify deposition of potentially toxic and fibrillogenic Aβ peptides in amyloidopathies. Specifically, the invention relates to the ability of memantine to intervene in the processing of APP and decrease the levels of fibrillogenic Aβ peptides.
Owner:FOREST LAB HLDG LTD
Aminediols for the treatment of Alzheimer's disease
The present invention relates to compounds of formula (I): useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.
Owner:PHARMACIA & UPJOHN CO
Benzamide 2-hydroxy-3-diaminoalkanes
The present invention relates to compounds of formula (I):useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are also useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.
Owner:ELAN PHARM INC
Hydroxypropylamines
Disclosed are compounds of formula I:and the pharmaceutically acceptable salts thereof wherein the variables RN, R1, R2, R3, RP and RC are defined herein. These compounds are useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.
Owner:PHARMACIA & UPJOHN CO
Immunogenic compositions of cyclic peptides derived from the beta-amyloid peptide
InactiveUS20080107649A1Inhibition formationReduce chancePeptide/protein ingredientsViral antigen ingredientsCyclic peptideAdjuvant
Owner:PEVION BIOTECH
Diaminediols for the treatment of Alzheimer's disease
The present invention relates to compounds of formula (I):useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.
Owner:PHARMACIA & UPJOHN CO
2-Amino- and 2-thio- substituted 1,3-diaminopropanes
InactiveUS20050267199A1Suppression problemInhibit productionBiocideNervous disorderGreek letter betaThio-
Disclosed are compounds of the formula: where variables Q, Z, X, R15, R2, R3, and Rc are defined herein. Compounds disclosed herein are inhibitors of the beta-secretase enzyme and are therefore useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal.
Owner:ELAN PHARM INC
Beta-peptides with antifungal activity
The present invention is directed to the design, synthesis and use of various β-peptides exhibiting antifungal activity. The β-peptides are relatively short in length, adopt globally amphiphilic conformations, and cause little lysis of human red blood cells at concentrations that kill Candida albicans, a common human fungal pathogen.
Owner:WISCONSIN ALUMNI RES FOUND
Substituted amino carboxamides for the treatment of Alzheimer's disease
The present invention relates to compounds of formula (I): useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.
Owner:PHARMACIA & UPJOHN CO +1
Methods of treating alzheimer's disease using aryl alkanoic acid amides
Disclosed are methods for treating Alzheimer's disease, and other diseases, and / or inhibiting beta-secretase enzyme, and / or inhibiting deposition of A beta peptide in a mammal, by use of compounds of formula (1) wherein the variables R1-R8 and X are defined herein.
Owner:ELAN PHARM INC
Beta-polypeptide foldamers of well-defined secondary structure
InactiveUS6613876B1Improve stabilityPeptide librariesOrganic compound preparationProtein secondary structureCombinatorial chemistry
Disclosed are beta-peptides containing cylcoalkyl, cycloalkenyl, and heterocylic substituents which encompass the alpha and beta carbons of the peptide backbone. The beta-peptides adopt stable helical and sheet structures in both the solid state and in solution. Method of generating combinatorial libraries of peptides containing beta-peptide residues and the libraries formed thereby are disclosed.
Owner:WISCONSIN ALUMNI RES FOUND
Acetyl 2-hydroxy-1, 3-diaminoalkanes
InactiveUS7244725B2Suppression problemInhibit productionBiocideNervous disorderAlzheimer's diseaseEnzyme
Disclosed are compounds of the formula:where variables Z, X, R15, R2, R3, and RC are defined herein. Compounds disclosed herein are inhibitors of the beta-secretase enzyme and are therefore useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal.
Owner:PHARMACIA & UPJOHN CO +1
Benzamide 2-hydroxy-3-diaminoalkanes
The present invention relates to compounds of formula (I): useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are also useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.
Owner:ELAN PHARM INC
Methods of treating alzheimer's disease
Disclosed are methods for treating Alzheimer's disease, and other diseases, and / or inhibiting beta-secretase enzyme, and / or inhibiting deposition of A beta peptide in a mammal, by use of 3,4-disubstituted piperidinyl compounds of formula (I) wherein the variables R1, R2, R3, R4, Q, W, X, Z, m, and n are defined herein.
Owner:NIEMAN JAMES +2
Substituted ureas and carbamates
InactiveUS7351738B2Preventing and delaying onsetSuppression problemBiocideUrea derivatives preparationCarbamateMammal
The invention provides compounds of formula I:useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.
Owner:PHARMACIA & UPJOHN CO +1
Method of making biologically active alpha-beta peptides
ActiveUS20100099185A1Improved pharmacokineticImproved pharmacodynamic propertyPeptide/protein ingredientsVirus peptidesMolecular biologyBeta-peptide
Described is a method of fabricating biologically active, unnatural polypeptides. The method includes the steps of selecting a biologically active polypeptide or biologically active fragment thereof having an amino acid sequence comprising α-amino acid residues, and fabricating a synthetic polypeptide that has an amino acid sequence that corresponds to the sequence of the biologically active polypeptide, but wherein about 14% to about 50% of the α-amino acid residues found in the biologically active polypeptide or fragment of step (a) are replaced with β-amino acid residues, and the α-amino acid residues are distributed in a repeating pattern.
Owner:WISCONSIN ALUMNI RES FOUND
Allylamides useful in the treatment of alzheimer's disease
InactiveUS20050027007A1Suppression problemInhibit productionBiocideNervous disorderGreek letter betaMedicine
Disclosed are methods for treating Alzheimer's disease, and other diseases, and / or inhibiting beta-secretase enzyme, and / or inhibiting deposition of A beta peptide in a mammal, by use of compounds of formula (I) where R1, R2, R3, B, J1, J2, X and Z are as defined herein.
Owner:ELAN PHARM INC
2-amino- and 2-thio- substituted 1,3-diaminopropanes
Owner:ELAN PHARM INC
Acetyl 2-hydroxy-1, 3-diaminoalkanes
InactiveCN1694870APrevent or delay onsetOrganic chemistryAmide active ingredientsDiseaseAlzheimer Syndrome
The invention discloses compounds of chemical formula (I), wherein variable Z, X, R 15 , R 2 , R 3 , R c defined in this article. The compounds disclosed herein are inhibitors of β-secretase and are therefore useful in the treatment of Alzheimer's disease and other diseases in mammals characterized by the deposition of β-peptides.
Owner:ELAN PHARM INC +1
Aminediols for the treatment of Alzheimer's disease
The present invention relates to compounds of formula (I):useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.
Owner:PHARMACIA & UPJOHN CO
Substituted amines for the treatment of alzheimer's disease
InactiveUS20060100196A1Suppression problemInhibit productionBiocideNervous disorderGreek letter betaEnzyme
Disclosed are compounds of formula (I) which are useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.
Owner:ELAN PHARM INC
Screening and anti-tumor application of KRAS mutation specific T cell receptor
ActiveCN112300269AEffectively identify and killGrowth inhibitionNucleic acid vectorFermentationEpitopeImmune effects
The invention provides two specific T cell receptors targeting G12V or G12C mutation epitopes of a KRAS gene and an anti-tumor application. The two T cell receptors respectively consist of an alpha peptide chain and a beta peptide chain. The invention also provides an antigen binding fragment of the T cell receptors, nucleic acid encoding the antigen binding fragment, a vector containing the nucleic acid, and a host cell containing the vector. The invention further provides a method for preparing a G12V mutation-specific T cell receptor of KRAS or an antigen-binding fragment thereof. The specific T cell receptor and the antigen binding fragment thereof can be used as immune effect activators to stimulate the immune response of the body, thereby generating the action effect of resisting tumors and other diseases.
Owner:INST OF MICROBIOLOGY - CHINESE ACAD OF SCI
Beta-amino acids
InactiveUS20020037997A1High conformational stabilityImprove stabilityPeptide librariesOrganic compound preparationCombinatorial chemistryPeptide backbone
Disclosed are beta-amino acid monomers containing cylcoalkyl, cycloalkenyl, and heterocylic substituents which encompass the alpha and beta carbons of the peptide backbone and beta-polypeptides made from such monomers. Method of generating combinatorial libraries of polypeptides containing the beta-peptide residues and libraries formed thereby are disclosed.
Owner:WISCONSIN ALUMNI RES FOUND
Beta-peptide lyotropic liquid crystals and methods of manufacture and use thereof
ActiveUS20100021344A1Increased birefringenceLiquid crystal compositionsPeptide/protein ingredientsCrystallographyProviding material
The present invention provides materials and methods that make liquid crystal phases accessible with relatively short β-peptides in aqueous solvents.
Owner:ALCATEL LUCENT SAS +1
Methods for treating alzheimer's disease using quinaldoyl-amine derivatives of oxo-and hydroxy-substituted hydrocarbons
Disclosed are methods for treating Alzheimer's disease, and other diseases, and / or inhibiting beta-secretase enzyme, inhibiting beta-secretase enzyme, and / or inhibiting deposition of A beta peptide in a mammal, by use of compounds of of compounds of formula (I) wherein R1, R2, R3. and N, are defined herein.
Owner:PHARMACIA & UPJOHN CO
Macrocycles useful in the treatment of Alzheimer's disease
Owner:ELAN PHARM INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com